Mirum Pharmaceuticals (MIRM) Net Cash Flow (2019 - 2026)

Mirum Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 353.47% year-over-year to $29.7 million in Q1 2026; TTM through Mar 2026 was $113.5 million, a 225.77% increase from a year earlier, with the FY2025 full-year figure at $72.0 million, up 215.96% from the prior year.
• Net Cash Flow improved to $29.7 million in Q1 2026 per MIRM's latest filing, from $16.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $147.9 million in Q2 2023 and bottomed at -$69.2 million in Q2 2024.
• The 5-year median for Net Cash Flow is $9.0 million (2022), against an average of $11.5 million.
• Across the five-year window, Net Cash Flow slumped 265.78% in 2024 and soared 1660.35% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$7.8 million in 2022, then sank by 114.78% to -$16.8 million in 2023, then jumped by 105.42% to $913000.0 in 2024, then surged by 1660.35% to $16.1 million in 2025, then soared by 85.09% to $29.7 million in 2026.
• Per Business Quant, the three latest MIRM Net Cash Flow figures stand at $29.7 million (Q1 2026), $16.1 million (Q4 2025), and $53.6 million (Q3 2025).